THIERRY BOURBIÉ, CO-founder, CHIEF EXECUTIVE OFFICER & CHAIRMAN
Thierry is, since 2005, the CEO and Chairman of Pharmaleads. He is responsible for establishing the Company’s drug development strategy. Prior to joining the Company, he served as Deputy General Manager of Suez Environment, the world leader in water distribution. He has also held numerous Board positions in different companies, some of them listed on the New York and Madrid stock exchanges. Before that, he worked for the Schlumberger Group where he held commercial and marketing responsibilities world-wide, as well as for the French Institute of Petroleum in the area of oil exploration and production.
Thierry is a graduate from Ecole Polytechnique and Ecole des Mines in Paris and a Doctor in Geophysics from Stanford University, California.
Thierry together with Bernard P. Roques and Marie-Claude Fournié-Zaluski, co-founded Pharmaleads.
PIERRE MAILLARD, CHIEF FINANCIAL OFFICER
Pierre is CFO of Pharmaleads since 2007. He brings with him a strong international background in financial administration and control, development, project negotiation and management in different industries worldwide: Dassault aviation, Suez environment and in the automotive industry within listed SMEs or large corporations.
Pierre holds an MBA from ESSEC Business School in Paris and an MSc in International Finance from Strasbourg University.
MICHEL WURM, VP, MEDICAL AFFAIRS, STRATEGY & BUSINESS DEVELOPMENT
Michel joined Pharmaleads in 2006 to head the corporate development and oversee preclinical and clinical developments of the Company’s products. He has extensive experience across all aspects of drug development, with a focus on clinical trials. Prior to joining Pharmaleads Michel was Corporate Development Director of French biotech Imaxio. He has also held international positions in Pharma companies (Novartis, Galderma) and with CROs bringing several new chemical entities to registration.
Michel wrote the French adaptation of the Investigator’s Guide to Clinical Research (Centerwatch, Boston, 2002).
Michel is a graduate from the School of Medicine of Clermont-Ferrand, France.
TANJA OUIMET, DIRECTOR OF CLINICAL DEVELOPMENT
Tanja joined Pharmaleads in 2006 to head the Biochemistry laboratory, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. In 2014, Tanja was appointed Head of Clinical Operations overseeing the DENKIs clinical trials. She is currently Director of Clinical Development. Before that, Tanja joined the INSERM U109 Unit in Paris in 1996 where she pursued her research on metalloproteases as drug targets.
Tanja has authored more than 30 publications in highly respected international journals and she is also co-inventor of 4 patents.
She holds a PhD in Neurosciences from the University of Montréal which she completed at the Institute of Clinical Research of Montréal.
HERVÉ PORAS, DIRECTOR OF CMC AND PRECLINICAL OPERATIONS
Hervé joined Pharmaleads in 2002 to serve as Head of the Chemistry Department for the synthesis of Dual Enkephalinase Inhibitors (DENKIs) and zinc metalloprotease peptide substrates. He has been in charge of DENKI preclinical development since PL37 was chosen as the first drug candidate to go into clinical development. Since 2017, he serves as Director of CMC and Preclinical Operations. Before that, he spent 2 years as a Post-Doc at Sagami Chemical Research Center near Tokyo (Japan)
Hervé is co-inventor of 10 patents and co-author of more than 20 publications in international journals.
He is a graduate from Ecole Nationale Supérieure de Chimie in Paris and holds a PhD in Organic Chemistry from Orsay University (Paris XI).